^
Association details:
| Biomarker: | CD19 positive |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | puqilunsai (pCAR-19B) (CD19-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The Safety and Efficacy of p CAR-19B, a Scfv Humanlized CD19-Directed CAR-T for Patients with Relapsed/Refactory (R/R) CD19+ B-ALL
Published date:
11/03/2022
Excerpt:
As of June 30, 2022, nine patients (3 in DL1, 6 in DL2) were infused with pCAR-19B and all patients have finished at least 6 months follow up visit. Demographics, baseline disease, prior treatment and special concerned adverse events are presented in the table...pCAR-19B has demonstrated a good safe profile and 100% CR rate in phase I study for adults R/R CD19+ B-ALL.
DOI:
https://doi.org/10.1182/blood-2022-162134
Trial ID:
